Drug Trial Radar · NCT05300035
Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
69
Planned (sponsor's estimate)
Start
Apr 11, 2024
Primary completion
Dec 10, 2026
Study completion Dec 10, 2028
Sponsor
- Lead sponsor
- ANRS, Emerging Infectious DiseasesGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Rockefeller University; Institut Pasteur
- First posted
- Mar 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RHIVIERA-02 trial is a placebo-controlled double-blinded two arm prospective phase II trial. This study will test the use of broadly neutralising antibodies (bNAbs) in participants, at primary HIV infection (PHI) and ART initiation.
Conditions
- HIV/AIDS and Infections
Interventions
Recombinant human monoclonal antibody (bNAbs)Drug
1. Initiation of combination ART (1 integrase inhibitor + 2 nucleoside analogue reverse transcriptase inhibitors) with additional dual intravenous infusions of bNAbs (3BNC117LS \& 10-1074LS) between Day 7 and Day 10. 2. Analytical treatment interruption (ATI), 52 weeks later, if good immunologic and virologic conditions. 3. During ATI, plasma HIV-1 RNA and CD4 monitoring, for a maximum of 48 weeks. 4. ART resumption, if participant encounters at least one ART resumption criteria.
PlaceboDrug
1. Initiation of combination ART (1 integrase inhibitor + 2 nucleoside analogue reverse transcriptase inhibitors) with additional dual intravenous infusions of placebo (saline solution) between Day 7 and Day 10. 2. Analytical treatment interruption (ATI), 52 weeks later, if good immunologic and virologic conditions. 3. During ATI, plasma HIV-1 RNA and CD4 monitoring, for a maximum of 48 weeks. 4. ART resumption, if participant encounters at least one ART resumption criteria.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with plasma HIV-1 RNA below 400 cp/mL 24 weeks following ATI (W24 ATI), in the confirmed absence of ART.Time frame: at Week 24 of antiretroviral treatment interruption period (ATI)
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Hôpial Avicenne - SMIT
Bobigny, France · Recruiting
Hôpital Antoine Béclère
Clamart, France · Recruiting
Hôpital Beaujon - Service de médecine interne
Clichy, France · Recruiting
CHI Créteil - HdJ
Créteil, France · Recruiting
Hôpital Raymond Poincaré - SMIT
Garches, France · Recruiting
Hôpital Bicêtre - HdJ - Médecine interne
Le Kremlin-Bicêtre, France · Recruiting
Hôpital Hôtel - Dieu
Paris, France · Recruiting
Hôpital Hôtel Dieu - Service d'immunologie clinique
Paris, France · Not yet recruiting
Hôpital Pitié-Salpêtrière - SMIT
Paris, France · Recruiting
Hôpital Lariboisière - Service de médecine interne A
Paris, France · Recruiting
Hôpital Saint- Louis - SMIT
Paris, France · Recruiting
Hôpital Saint-Antoine - SMIT
Paris, France · Recruiting
Hôpital Necker - SMIT
Paris, France · Recruiting
Hôpital Bichat - Claude Bernard - SMIT
Paris, France · Recruiting
Hôpital Tenon - SMIT
Paris, France · Recruiting
Centre médico chirurgical Foch - Suresnes
Suresnes, France · Recruiting
CHI Villeneuve-Saint-Georges - SMIT
Villeneuve-Saint-Georges, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.